Press Releases
September 10, 2020
TFF Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Fierce Pharma: Union, TFF team up to fight COVID-19 with inhaled tapeworm medAugust 25, 2020
Fierce Pharma: Union, TFF team up to fight COVID-19 with inhaled tapeworm med
Outsourcing-Pharma.com: TFF, Union Therapeutics join on potential COVID-19 treatmentAugust 24, 2020
Outsourcing-Pharma.com: TFF, Union Therapeutics join on potential COVID-19 treatment
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamideAugust 13, 2020
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamide
TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business ResultsAugust 13, 2020
TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business Results
Austin Statesman: Austin’s TFF Pharmaceuticals raises $25.9M with stock offeringAugust 11, 2020
Austin Statesman: Austin’s TFF Pharmaceuticals raises $25.9M with stock offering
TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology PlatformAugust 11, 2020
TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology Platform
TFF Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 13, 2020August 4, 2020
TFF Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 13, 2020
TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical TrialJuly 30, 2020
TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial
TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral TreatmentJuly 29, 2020
TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment